Reckitt Benckiser Group plc
OTC: RBGLY
Stock price
13.89 USD
(-45.87%) 5 years
Financial Performance
5Y price score: (70)
against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index,
while a score above 100 means it outperformed the S&P 500.
10Y return: (29.6)%
US$ Per
Share
Earnings per share
Free cash flow per share
Stock price
By default your notes are visible only to you.
12.7
52-week range
17.8
Your model inputs
| Required return / cost of capital |
| FCFF terminal growth rate |
Valuation
Free Cash Flow Yield
3.8 %
Dividend Yield TTM
8.9 %
Market cap $
$ 44,830.2
Price / Earnings TTM
14.5
Price / Book TTM
4.3
PEG TTM
0.1
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
(18.2) %
(36) %
(29.6) %
Free cash flow per share growth
(16.6) %
(39.8) %
16.9 %
Earnings per share growth
131.7 %
187.9 %
97.9 %
Founded: 2,007
Employees: 40,000
Business Summary:
all figures in GBP Millions except per share data
Periods:
View:
Forecast:
Averages
based on historical growth rates (CAGR) and average margins for last 10 or max, available and up to 10 years.
Analysts
Average Revenue and Net Income forecast estimates from analysts who cover the stock.
Custom
you can edit default forecast based on averages or analysts consensus and use it to calculate fair value based on your assumptions.
ㅤ
Please log in / sign up view historical financials. It is free under TopFunds
Light plan.
Increase
Decrease
Total
| Required return / cost of capital |
| FCFF terminal growth rate |
| Free cash flow forecast |
| Terminal value |
| ㅤPV breakdown |
| Enterprise value / PV of FCF |
| ㅤPlus / (Less): Net Debt |
| ㅤLess: preferred stock |
| ㅤLess: minority interest |
| Market cap |
| ㅤNumber of shares |
| Price per share |
Please log in / sign up to calculate fair value based on selected inputs
Latest Earnings Call Takeaways
2025 Q4 (Mar 5, 2026)
1) Financial Performance Overview
- Core Reckitt net revenue grew 5.2% YoY, exceeding guidance of above 4%.
- Group net revenue increased 5%, with Mead Johnson Nutrition up 3.8%.
- Adjusted operating profit rose 5.3%, with core margins expanding 90 basis points to 26.7%.
- EPS grew 1.1%, supported by a share buyback program, with GBP 2.3 billion returned to shareholders through dividends and buybacks.
2) Segment Results and Growth Drivers
- Emerging Markets: Strong growth of 14.6% in net revenue, driven by double-digit growth in China and India.
- Developed Markets: Weaker performance due to a tough consumer environment and a soft cold and flu season, with net revenue in Europe declining 1.4%.
- North America: Flat revenue growth at 0.2%, but nonseasonal brands showed resilience with low single-digit growth.
- Category Performance: Intimate Wellness was the fastest-growing category at 12.5%, while Household Care saw a slight decline of 0.4%.
3) Operational and Strategic Initiatives
- Continued focus on the Fuel for Growth program, which is driving simplification and effectiveness across the business.
- Significant investments in supply chain improvements, with CapEx rising to GBP 592 million in 2025.
- Innovations such as the Durex Intensity condom launched in 18 countries and new product extensions across various brands.
- Plans to enhance omnichannel capabilities, particularly in North America, to drive growth and improve customer access.
4) Challenges and Market Headwinds
- The consumer environment in Europe remains challenging, with promotional intensity increasing and category growth slowing.
- Seasonal OTC brands faced declines due to a weak cold and flu season, impacting overall performance in developed markets.
- Anticipated increase in fixed costs in 2026 due to stranded costs from the Essential Home divestiture, although expected to decline below 19% by 2027.
5) Guidance and Outlook for 2026
- Guidance for 2026 includes 4% to 5% net revenue growth, primarily driven by emerging markets.
- Expectation of continued challenges in Europe, particularly in Q1, which may see growth below full-year guidance.
- Strategic focus on maintaining market share and driving premiumization across categories, particularly in Europe and North America.
- The company is exploring strategic options for Mead Johnson Nutrition, with no specific timeline set for potential changes.
Bottom line: Reckitt delivered solid financial results in 2025, driven by strong performance in emerging markets and effective operational strategies. However, challenges in developed markets and increasing costs may pressure margins in 2026. The focus on innovation and premiumization positions the company for sustainable growth, making it a potentially attractive investment for shareholders.
Reckitt Benckiser Group plc — Financial Overview, Stock Price, Market Cap
Reckitt Benckiser Group plc is a company. Founded in 2007. As of April 13, 2026, the company's market capitalization is $44830158723 with a current stock price of $13.89.